India’s Micro Therapeutic says EMA’s ‘Sweep’ Suspension Will Hurt; CRO Industry Shuns ‘Bad Eggs’
Executive Summary
Data integrity concerns continue to cloud outlook for India’s contract research sector. The European Medicines Agency’s latest action against Micro Therapeutic Research Labs suspends more than 300 products in the EU over “unreliable” data and the firm tells Pink Sheet this will result in a “considerable dent” in its operations.
You may also be interested in...
Indian Firms’ US Revenues Slow Sharply But Balance Sheets Still Solid
US revenues of Indian pharmaceutical companies have slowed sharply amid a blitz of regulatory inspections and consolidation of the US purchasing chain -- but the news is not all bad: balance sheets are solid, margins are healthy and longer-term prospects look positive, says leading Indian investment rating agency ICRA.
Data Integrity Failures Undermine Trust That Can’t Easily Be Won Back, EMA Official Says
A forum on quality excellence in India saw global regulators highlight regulatory requirements and expectations in critical areas such as data integrity and the investigation of compliance-related complaints. The fostering of a quality culture was another key theme at the event, with one EMA speaker noting there are no easy fixes when trust in data is broken.
India Global Trial Hub Dreams Still Distant As Concerns Linger
Indian clinical trial approvals appear to be on the downswing despite government moves to boost the troubled sector, as regulatory uncertainty and negative publicity continue to undermine confidence in the industry.